About Enzo Biochem
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: ENZ
- Previous Close: $6.66
- 50 Day Moving Average: $6.78
- 200 Day Moving Average: $6.29
- 52-Week Range: $46,289,000.00 - $4.00
- Trailing P/E Ratio: 7.92
- Foreward P/E Ratio: -37.00
- P/E Growth: 0.00
- Market Cap: $308.28M
- Outstanding Shares: 46,289,000
- Beta: 1.4
- Net Margins: 37.91%
- Return on Equity: -12.25%
- Return on Assets: -9.21%
Companies Related to Enzo Biochem:
- Current Ratio: 4.35%
- Quick Ratio: 4.01%
What is Enzo Biochem's stock symbol?
Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."
When will Enzo Biochem announce their earnings?
Enzo Biochem is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
Who owns Enzo Biochem stock?
Enzo Biochem's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Evermore Global Advisors LLC (7.16%), Renaissance Technologies LLC (4.25%), Dimensional Fund Advisors LP (4.08%), First Light Asset Management LLC (2.18%), State Street Corp (1.23%) and Arrowstreet Capital Limited Partnership (0.87%).
Who sold Enzo Biochem stock? Who is selling Enzo Biochem stock?
Enzo Biochem's stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, First Light Asset Management LLC, Kopp Investment Advisors LLC, O Shaughnessy Asset Management LLC, Dimensional Fund Advisors LP and Metropolitan Life Insurance Co. NY.
Who bought Enzo Biochem stock? Who is buying Enzo Biochem stock?
Enzo Biochem's stock was bought by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Arrowstreet Capital Limited Partnership, Putnam Investments LLC, Russell Investments Group Ltd., GSA Capital Partners LLP, Perceptive Advisors LLC, Oxford Asset Management and State Street Corp.
How do I buy Enzo Biochem stock?
Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Enzo Biochem stock cost?
One share of Enzo Biochem stock can currently be purchased for approximately $6.66.